Patents by Inventor Larry Kaiser

Larry Kaiser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of Non-Neuronal Cancer using HSV-1 Variants
    Publication number: 20110195053
    Abstract: A mutant herpes simplex virus which has been modified in the ?34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.
    Type: Application
    Filed: April 20, 2011
    Publication date: August 11, 2011
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, CRUSADE LABORATORIES LIMITED, WISTAR INSTITUTE
    Inventors: Susanne M. Brown, Alasdair R. Maclean, Nigel W. Fraser, Bruce P. Randazzo, Steven Albelda, Larry Kaiser, John Kucharczuk
  • TREATMENT OF NON-NEURONAL CANCER USING HSV-1 VARIANTS
    Publication number: 20070292394
    Abstract: A mutant herpes simplex virus which has been modified in the ?34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.
    Type: Application
    Filed: June 19, 2007
    Publication date: December 20, 2007
    Inventors: Susanne Brown, Alasdair Maclean, Nigel Fraser, Bruce Randazzo, Steven Albelda, Larry Kaiser, John Kucharczuk
  • Treatment of non-neuronal cancer using HSV-1 variants
    Publication number: 20050226850
    Abstract: A mutant herpes simplex virus which has been modified in the ?34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.
    Type: Application
    Filed: June 8, 2005
    Publication date: October 13, 2005
    Inventors: Susanne Brown, Alasdair MacLean, Nigel Fraser, Bruce Randazzo, Steven Albelda, Larry Kaiser, John Kucharczuk
  • Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
    Patent number: 6428968
    Abstract: The invention includes methods, compositions, and kits for killing tumor cells in a subject such as a human patient. The methods comprise administering both a chemotherapeutic agent and an oncolytic virus other than an adenovirus to a subject which has tumor cells. The agent and virus exhibit oncolytic activities that are at least additive, and that may be synergetic. The oncolytic virus may, for example, be a herpes simplex virus (type 1 or 2), a vaccinia virus, a vesicular stomatitis virus, or a Newcastle disease virus. The compositions and kits comprise a chemotherapeutic agent and an oncolytic virus other than an adenovirus, either in admixture or separately.
    Type: Grant
    Filed: November 8, 1999
    Date of Patent: August 6, 2002
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Katherine Molnar-Kimber, Larry Kaiser, Takane Toyoizumi